Sign In
Buy AIM
$0.266
-0.0170 (-6.01%)
At Close: Jul 13, 2026
AIM ImmunoTech Announces Release of New CEO Corner Segment Highlighting Growing Momentum Across Pancreatic Cancer Program
09:03am, Tuesday, 07'th Jul 2026
CEO Thomas Equels discusses recent clinical progress, upcoming milestones and the Company's commitment to advancing Ampligen® for patients with pancreatic cancer CEO Thomas Equels discusses recent cl
Coiled Therapeutics develops improved formulation of experimental cancer drug ahead of trial expansion
02:27am, Tuesday, 07'th Jul 2026
Coiled Therapeutics (AIM:COIL, OTCQB:COTXF), a clinical-stage oncology company developing medicines for hard-to-treat cancers, has created a new oral formulation of its lead drug candidate designed to
Phoenix Copper shares drop on discount equity raise
05:12am, Monday, 06'th Jul 2026
Phoenix Copper Ltd (AIM:PXC, OTCQX:PXCLF, FRA:5HR) said it plans to raise around £2.3 million through a placing and subscription at a steep discount, while warning that further funding will still be
Greatland Resources ramp-up continued through June 2026
03:28am, Monday, 06'th Jul 2026
Greatland Resources Ltd (AIM:GGP, OTC:GRLGF, FRA:G8G, ASX:GGP) told investors that its full-year gold production topped guidance after a June quarter that also lifted its cash balance to almost US$1
Update on Intention to Move from AIM to Main Market
02:00am, Friday, 03'rd Jul 2026
Reykjavík, July 03, 2026 (GLOBE NEWSWIRE) -- THIS ANNOUNCEMENT IS MADE FOR INFORMATION PURPOSES ONLY AND DOES NOT CONSTITUTE AN OFFER TO SELL OR ISSUE OR SOLICITATION TO BUY, SUBSCRIBE FOR OR OTHERWI
OCALA, Fla., June 24, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today highlighted the significant progress achieved across its pancreatic canc
Coiled Therapeutics appoints biotech veteran Craig Tooman to board
06:58am, Wednesday, 24'th Jun 2026
Coiled Therapeutics (AIM:COIL, OTCQB:COTXF), the AIM-listed clinical-stage oncology company, has appointed Craig Tooman as an independent non-executive director with effect from 25 June. Tooman most r
AIM Sports Group's National SoCal Cup ‘The Showcase' Event Serves Up a Weekend of New Experiences
02:24pm, Tuesday, 23'rd Jun 2026
LOS ANGELES--(BUSINESS WIRE)-- #aimsportsgroup--AIM Sports Group hosted the SoCal Cup ‘Showcase' tournament, one of the nation's leading tournament series for youth club volleyball, at the Los Angel
OUST's AIM Partnership Validates Rev8's Commercial Promise
11:01am, Tuesday, 23'rd Jun 2026
Ouster's AIM supply deal puts its Rev8 lidar into autonomous mining and construction fleets, offering a high-profile test of its commercial potential.
Metals One builds 5.57% stake in newly listed Talon Resources
03:04am, Tuesday, 23'rd Jun 2026
Metals One PLC (AIM:MET1, FRA:HT7, OTCQB:MTOPF), the gold and uranium developer and investor, has built a 5.57% stake in Talon Resources. The holding was confirmed as Talon began trading on AIM on Tu
Cavendish backs CelLBxHealth turnaround with buy rating, 4p target
10:35am, Monday, 22'nd Jun 2026
Cavendish remains bullish on CelLBxHealth PLC (AIM:CLBX, FRA:DWV) with a 'buy' rating and 4p price target in the wake of its prelims earlier. The AIM-listed biotech has completed a strategic reset c
AIM ImmunoTech to Present in the Webull Corporate Connect Webinar Series
08:45am, Monday, 22'nd Jun 2026
OCALA, Fla., June 22, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that it will present in the Webull Corporate Connect Webinar S
CelLBxHealth guides for 50% revenue growth as partnership pipeline swells
03:01am, Monday, 22'nd Jun 2026
CelLBxHealth PLC (AIM:CLBX, FRA:DWV), the circulating tumour cell diagnostics company, expects revenues of at least £2.1 million in 2026, representing growth of at least 50% from last year's £1.4 mi
Union Jack Oil 's Crossroads well disappoints with non-commercial result
03:35am, Friday, 19'th Jun 2026
Union Jack Oil PLC (AIM:UJO, OTCQB:UJOGF, FRA:1UJ0) said its Crossroads well in Garvin County, Oklahoma, has been deemed non-commercial following testing, marking a setback for the AIM-listed company'
Study results expected to support design and initiation of a pivotal Phase 3 clinical trial in the treatment of metastatic pancreatic cancer Study results expected to support design and initiation of
